Immunicum

36 articles about Immunicum

• Immunicum AB (publ) Announces Upcoming Investor Events in October and November 2018

  10/23/2018

  Immunicum AB announced today that the Company will participate in and host investor events in October and November.

• Immunicum AB (publ) Announces Nomination Committee for AGM 2019

  10/20/2018

  Immunicum AB (publ) in accordance with the principles of appointing the Nomination Committee, adopted by the Annual General Meeting of April 25, 2018, announced today that the members of the Nomination Committee have been appointed.

• Notice of Extraordinary General Meeting in Immunicum AB (publ)

  10/17/2018

  The shareholders of Immunicum AB (publ) (the "Company"), reg. no 556629-1786, hereby summon to Extraordinary General Meeting on Thursday, 8 November 2018, at 14:30 p.m. at United Spaces, Östra Hamngatan 16, SE-411 Gothenburg, conference room Arenan. Registration for the meeting will commence at 14:00 p.m.

• Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration

  10/1/2018

  Immunicum AB today announced that Nasdaq Stockholm decided to halt trading in the Company's share as a result of share price movements.

• Immunicum AB (publ) Announces Upcoming Presentations at Conferences in October 2018

  9/28/2018

  Immunicum AB (publ; IMMU.ST) today announced that Company leadership will present at upcoming regulatory affairs, industry and scientific conferences in October.

• Immunicum AB (publ) Interim Report April - June 2018

  8/17/2018

  Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer.

• Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress

  8/13/2018

  Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018 in Munich, Germany.

• Immunicum AB Presents Case Study of One Patient From Phase I/II HCC Trial at Cholangiocarcinoma Foundation Annual Conference

  2/5/2018

  In the study, the bile duct cancer patient first received a transarterial chemo-embolization (TACE), which is a standard method to deliver a chemotherapeutic drug directly to the tumor while also restricting blood supply to the tumor.

• Michaela Gertz Joins Immunicum as CFO

  1/31/2018

  Lise-Lotte Hallbäck will leave her position as CFO of Immunicum as of today to pursue other interests.

• Change in the Number of Shares and Votes in Immunicum

  1/31/2018

  The number of shares and votes in Immunicum has, as a result of a rights issue of shares, increased with 24,999,990, from 25,958,541 to 50,958,531.

• Immunicum AB (Publ) Initiates Trading of Shares on Nasdaq Stockholm

  1/15/2018

  Immunicum is listed as a small cap company within the healthcare sector.

• Immunicum Completes Strategic Analysis And Defines Updated Clinical Development Plan For Ilixadencel

  8/17/2017

• Immunicum Announces Publication In Journal For Immunotherapy Of Cancer Of Results Overview From Ilixadencel's First Clinical Study In Metastatic Renal Cell Carcinoma

  6/20/2017

• Accelovance Selected To Advance Immunicum’s INTUVAX Oncology Immunotherapy Pipeline

  5/20/2016

• Immunicum Reports Positive Phase I/II-Data For The Therapeutic Cancer Vaccine INTUVAX® In The Treatment Of Kidney Cancer

  12/5/2013

• Immunicum's Patent Application Regarding the Company’s Core-Technology for Therapeutic Cancer Vaccination Using Allogeneic Dendritic Cells is Being Approved in the U.S.

  10/25/2013